Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

AIDS

Volumn 17, Issue 2, 2003, Pages 201-208

  Brumme, Zabrina L ^a   Dong, Winnie W Y ^a   Chan, Keith J ^a   Hogg, Robert S ^a   Montaner, Julio S G ^a,b   O'Shaughnessy, Michael V ^a,b   Harrigan, P Richard ^a,b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral therapy; CX3CR1; MDR 1; P glycoprotein; Polymorphisms

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR1; DNA; GENE PRODUCT; MULTIDRUG RESISTANCE PROTEIN 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; ARTICLE; CANADA; DNA SEQUENCE; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; GENE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MULTIVARIATE ANALYSIS; PHYSIOLOGY; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; GENE FREQUENCY; GENES, MDR; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEMBRANE PROTEINS; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CHEMOKINE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; VIRAL LOAD;

EID: 0037462209     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200301240-00010     Document Type: Article

References (37)

1. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996, 35:3362-3367.
2. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
3. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
4. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996, 11:1240-1243.
5. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
6. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
7. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996, 382:722-725.
8. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, et al. Increased frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 1997, 11:1833-1838.
9. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998, 273:23799-23804.
10. Rucker J, Edinger A, Sharron M. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997, 71:8999-9007.
11. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000, 287:2274-2277.
12. 3CR1 and risk of HIV disease. Science 2000, 290:2031.
13. Brumme ZL, Chan KJ, Dong W, Hogg R, O'Shaughnessy MV, Montaner JS, et al. CCR5 Δ32 and promoter polymorphisms are not correlated with initial virological and immunological treatment reponse. AIDS 2001, 15:2259-2266.
14. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998, 12:2193-2202.
15. Guerin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, et al. CCR5 delta32 deletion and response to HAART in HIV-1-infected patients. SEROCO/HEMOCO Study Group. AIDS 2000, 14:2788-2790.
16. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000, 14:821-826.
17. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
18. Levêque D, Jehl F. P- glycoprotein and pharmacokinetics. Anticancer Res. 1995, 15:331-336.
19. Sarkadi B, Muller M, Homolya L, Hollo Z, Seprodi J, Germann UA, et al. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 1994, 8:766-770.
20. Sharom FJ, Yu X, DiDiodato G, Chu JW. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 1996, 320:421-428.
21. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998, 286:1439-1455.
22. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
23. Washington CB, Curan GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein in human cultured cells. J Acquir Immune Defic Syndr Humn Retrovirol 1998, 19:203-209.
24. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, et al. P-Glycoprotein and transporter MRP-1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001, 15:1353-1358.
25. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000, 14:237-242.
26. Hoffmeyer S, Burk O, von Richter O, Arnold HF, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478.
27. Gottesman MM, Pastan I, Ambudkar V. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996, 6:610-617.
28. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
29. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001, 11:293-298.
30. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001, 358:383-384.
31. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36.
32. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
33. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000, 23:360-361.
34. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002, 16:1051-1058.
35. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
36. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001, 15:1671-1677.
37. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR-1 gene in white subjects. Clin Pharmacol Ther 2001, 69:169-174.